ASLAN Pharmaceuticals and Bristol-Myers Squibb Enter Innovative Partnership
- Details
- Category: Bristol-Myers Squibb
ASLAN Pharmaceuticals Pte Ltd, a pharmaceutical company headquartered in Singapore, and Bristol-Myers Squibb Company (NYSE: BMY) announced an innovative strategic partnership allowing for the rapid development of BMS-777607, Bristol-Myers Squibb's investigational small molecule inhibitor of the MET receptor tyrosine kinase for treatment of solid tumors.
Sanofi net sales up 10.1% and Business net income up 4.1% at CER
- Details
- Category: Sanofi
Sanofi's net sales in the third quarter of 2011 were €8,753 million, an increase of 5.0% on a reported basis. Exchange rate movements had a negative effect of 5.1 percentage points, mainly due to a less favorable euro/U.S. dollar parity.
Lilly CEO Says Appropriate Assessment of Both Benefits and Risks Critical in Regulatory Process
- Details
- Category: Eli Lilly and Company
To sustain medical innovation, the FDA must accelerate the adoption of a Benefit-Risk framework to inform decision-making in the regulatory process, said John Lechleiter, Ph.D., chairman, president and CEO of Eli Lilly and Company (NYSE: LLY).
Abbott Receives U.S. FDA Approval for Next-Generation XIENCE PRIME(TM) Drug Eluting Stent
- Details
- Category: Abbott
Abbott (NYSE: ABT) has received U.S. Food and Drug Administration (FDA) approval for the next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.
Pfizer Reports Third-Quarter 2011 Results
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) today reported financial results for third-quarter 2011. Third-quarter 2011 revenues were $17.2 billion, an increase of 7% compared with the year-ago quarter, which reflects operational growth of $247 million, or 1%, and the favorable impact of foreign exchange of $951 million, or 6%.
Daiichi Sankyo Establishes New Vaccine Research Unit in Japan
- Details
- Category: Daiichi Sankyo
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has established a new Japanese vaccine research unit to be located in its Kasai R&D Center (Edogawa-ku, Tokyo).
Pfizer Completes Acquisition Of Icagen
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) has completed its acquisition of Icagen, Inc., through the merger of its wholly owned subsidiary, Eclipse Acquisition Corp., with and into Icagen. Icagen is now a wholly-owned subsidiary of Pfizer.
More Pharma News ...
- Shire continued strong product sales performance in Q3
- After a good third quarter: Bayer confirms Group outlook
- Bristol-Myers Squibb Delivers Strong Third Quarter
- AstraZeneca Third Quarter Results
- Amgen's Third Quarter Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent
- GSK delivers strong Q3 performance with underlying sales growth
- Merck Total Revenues Increase by 4% to € 2.5 Billion